Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/Cordis and Guidant arbitration

This article was originally published in The Gray Sheet

Executive Summary

Ruling on Lau patent disputes, in which Guidant asserts infringement by Cordis' BX Velocity and Omni BX stents, is expected in early 2004. Guidant's Lau patent infringement claims against J&J/Cordis will be the second patent issue decided under the firms' April 2000 stent patent arbitration and cross-licensing deal. An Aug. 20 arbitration panel upheld a June decision to award J&J/Cordis $425 mil. for the infringement of its Palmaz-Schatz patents by Guidant's Multi-Link Duet coronary stent system (1The Gray Sheet" June 9, 2003, p. 22). Guidant set aside the money following the initial ruling and will incur no further costs due to the cross-licensing arrangement...

You may also be interested in...



Guidant To Seek Review Of $425 Mil. Patent Suit Arbitration Award To Cordis

Guidant stent sales will not be affected by a June 5 arbitration panel finding that the firm infringed Johnson &Johnson/Cordis' Palmaz-Schatz patents, Guidant says

Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker

Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line

Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel